FdaApplication
NDA 218571
Identifiers
- fda_app_no: NDA218571
Properties
| Property | Value |
|---|---|
| applicant_name | MILESTONE PHARMACEUTICALS USA INC |
| application_type | NDA |
| approval_date | 2025-12-12 |
Revenue by product
CARDAMYST
| Period | Revenue |
|---|---|
| Q2 2026 | $0.6M† |
| Q1 2026 | $0.2M† |
| Q2 2025 | $0.0M† |
| Q1 2025 | $0.0M† |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A figure marked † is the company's one reported revenue line rather than a product breakdown.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| CARDAMYST | ETRIPAMIL | 70MG | SPRAY;NASAL |
1 product